Trial: 201903114

A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome after T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Phase

I

Principal Investigator

Abboud, Ramzi

Disease Site

Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Hodgkin’s Lymphoma; Lymphoid Leukemia; Myelodysplastic Syndrome (MDS); Myeloid and Monocytic Leukemia; Non-Hodgkin’s Lymphoma; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov